Abstract
Histone methyltransferase KMT2D is frequently mutated in lung tumors, and Alam et al. identify KMT2D as a lung tumor suppressor. KMT2D deficiency induces aberrant metabolic reprogramming via super-enhancer impairment, conferring sensitivity to glycolytic inhibitors in lung cancer with KMT2D-inactivating mutations.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 599-617.e7 |
| Journal | Cancer Cell |
| Volume | 37 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 13 2020 |
Keywords
- KMT2D
- epigenetic modifier
- glycolysis
- histone methylation
- histone methyltransferase
- inhibitor
- lung cancer
- metabolism
- super-enhancer
- tumor suppressor
ASJC Scopus subject areas
- Oncology
- Cancer Research
Fingerprint
Dive into the research topics of 'KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS